Buzz Stocks: Starbucks Corporation, Paypal Holdings Inc, and Puma Biotechnology Inc

Today's stocks to watch in the news include Starbucks Corporation (NASDAQ:SBUX), Paypal Holdings Inc (NASDAQ:PYPL), and Puma Biotechnology Inc (NYSE:PBYI)

Jul 22, 2016 at 10:46 AM
facebook twitter linkedin

U.S. stocks are modestly lower, as stocks react to mixed earnings. Among equities in focus today are specialty coffee retailer Starbucks Corporation (NASDAQ:SBUX), online payment firm Paypal Holdings Inc (NASDAQ:PYPL), and biotech stock Puma Biotechnology Inc (NYSE:PBYI).

  • SBUX is down 0.4% at $57.40, after issuing disappointing quarterly sales figures and lowering its full-year sales forecast. No fewer than seven analysts issued price-target cuts in the wake of the earnings announcement. Despite the miss, Starbucks Corporation shares are still just above breakeven year-over-year, and after their most recent test of the $54 area, have consolidated into the $56-$57.50 range. Option buyers were hoping for a post-earnings breakout to the upside, given SBUX's 50-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 2.13 -- in the 95th percentile of its annual range.
  • PYPL is down 7.6% at $37.07, after reporting earnings and announcing a partnership with former rival Visa Inc (NYSE:V). Wells Fargo reacted by downgrading PYPL to "market perform" from "outperform." Paypal Holdings Inc is now down 3.4% year-over-year and back below its 10-week moving average, following today's bear gap and another unsuccessful test of the $40-$41 region. With 21 of 35 analysts rating currently PYPL a "buy" or better, and with only three "sell" or worse ratings on the books, there's plenty of room for downgrades to push the shares lower.
  • PBYI is up 18.1% at $40.76, after releasing promising five-year survival results for its Phase III trial of breast cancer drug neratinib, and submitting a New Drug Application to the Food and Drug Administration (FDA). This is welcome news for the biotech, which is sitting above $40 for the first time since late March. PBYI is down nearly 60% year-over-year, but is set to close the week atop its 20-week trendline for just the second time since April 2015. Some short sellers are likely kicking rocks today, after short interest rose more than 11.4% in the previous reporting period, leaving 30.2% of Puma Biotechnology Inc's float sold short -- which would take 7.7 days of trading to cover, at PBYI's average daily volume.

Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners